
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic is poised for long-term success due to its promising pipeline of selective oral immunology therapies targeting various chronic inflammatory and autoimmune diseases. With positive results from the Phase 2 EMPhASIS trial, including a significant reduction in combined unique active (CUA) MRI lesions in patients with relapsing-remitting MS versus placebo, the company's Phase 3 ENSURE program in RMS is positioned for success. The company's strong focus on reducing clinical relapse and confirmed disability progression, combined with its differentiated dual-mechanism approach, makes it a promising investment opportunity in the life sciences sector.
Bears say
Immunic is a clinical-stage biopharmaceutical company that focuses on developing therapies for chronic inflammatory and autoimmune diseases. However, its lead product candidate, vidofludimus calcium, may face challenges in gaining market traction due to its niche targeting of neuroprotection and relapse prevention. Additionally, the recent reverse stock split, while addressing compliance and providing necessary capital, may signal underlying weakness in investor demand and introduce dilution risks.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares